The vaccine was shown to be 89.3 percent effective at preventing infection with the novel coronavirus in a phase 3 trial conducted in the U.K., the drugmaker announced Jan. 28.
Mr. Erck told CNBC Novavax hopes the FDA will allow it to use data from its U.K. trial, as the drugmaker’s 30,000-participant phase 3 clinical trial is still ongoing in the U.S.
The U.K.’s regulatory body will likely review the vaccine in April. Mr. Erck said the FDA review will come “probably a month after that,” but it could be delayed by a month or two if the FDA decides to wait for the U.S. trial data.
More articles on pharmacy:
How J&J’s COVID-19 vaccine compares to Moderna’s, Pfizer’s
Merck to manufacture J&J’s COVID-19 vaccine
Florida expands eligibility for COVID-19 vaccines at retail pharmacies, physician offices
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
